AASLD: American Association for the Study of Liver Diseases
Home | Contact Us
About Us | News | JoinPatients | AASLD Foundation | Special Interest Groups | Committees
 

AASLD/EASL HCV Special Conference 
|

AASLD/EASL Special Conference on Hepatitis C
Sheraton New York Times Square Hotel
New York City, New York
September 12 – 13

Due to overwhelming demand, registration for this event is now closed.

Course Directors
Adrian M. Di Bisceglie, MD, FACP; Michael W. Fried, MD; Alessio Michele Aghemo, MD, PhD; and Darius Moradpour, MD

Two major developments—the recommendation for birth cohort screening and the recent approval of all-oral treatment regimens—are poised to change the landscape of HCV patient care. This special conference brings together a distinguished faculty from around the world to discuss the pathogenesis,
diagnosis, and treatment of the disease.

At this event, you will learn about new therapeutic options that can cure the vast majority of patients. You will also leave the conference with insights on global epidemiology, barriers to care, and potential solutions to improve global access to therapy. 

Adrian Di Bisceglie, MD, FACP, "Hopes for participation from people from around the world."

Learning Objectives

  • To evaluate the impact of new strategies for screening of hepatitis C in the United States and abroad
  • To understand the changing global epidemiology of HCV infection
  • To recognize the strengths and limitations of recently approved therapeutic regimens
  • To evaluate new treatment regimens under development for HCV
  • To recognize barriers to care and identify potential solutions to improve global access to new HCV therapies

Target Audience
This live activity is designed for hepatologists, gastroenterologists, NPs/PAs, epidemiologists, pharmacists and others with an interest in hepatitis C epidemiology and therapy.

 Friday, September 12

Talk TitleFilter
 
Session 1: Public Health Aspects of HCV
8:10 am - 8:30 am
Birth Cohort Screening for HCV
Brian R. Edlin, MD
8:30 am - 8:50 am
Lessons from the Scottish Health Service and Other EU countries
David S. Goldberg, MD
8:50 am - 9:10 am
Changing Epidemiology of HCV Infection: Unsafe Injections and Other Modes of Transmission
John W. Ward, MD
9:10 am - 9:30 am
Curing HCV Decreases Morbidity and Mortality: Do We REALLY Need More Data?
Harry L.A. Janssen, MD, PhD
9:30 am - 9:50 am
Panel Discussion
 
Break
 
Session 2: Pathogenesis of HCV infection
10:10 am - 10:30 am
Mechanisms of Antiviral Drugs
Darius Moradpour, MD
10:30 am - 10:50 am
Viral Resistance: Perspectives for Clinicians
Jean-Michel Pawlotsky, MD, PhD
10:50 am - 11:10 am
Mechanisms of Non-Response to Antiviral Therapy in Cirrhotic Patients
Jordan J. Feld, MD
11:10 am - 11:30 am
Pathogenesis of HCV Associated Liver Cancer
Stanley M. Lemon, MD
11:30 am - 11:50 am
HCV Immunology and Vaccine Prospects
Christopher Walker, PhD
11:50 am - 12:10 pm
Panel Discussion
 
Lunch
 
Session 3: Therapeutic Options
1:30 pm - 1:50 pm
New Triple Therapy PEG/RBV Regimens for Genotype 1 (All Classes)
Michael P. Manns, MD
1:50 pm - 2:10 pm
Phase III trials of IFN-Free Regimens: Genotype 1
Stefan Zeuzem, MD
2:10 pm - 2:30 pm
Phase III trials of IFN-Free Regimens: Non-1 Genotypes
Ira M. Jacobson, MD
2:30 pm - 2:50 pm
HCV Drugs with Novel Mechanisms of Action (Lambda, microRNA, etc.)
Heiner Wedemeyer, MD
2:50 pm - 3:10 pm
Panel Discussion
3:10 pm - 4:15 pm
Poster Session
 
Session 4: Therapeutic Challenges
4:15 pm - 4:35 pm
Genotype 3: All Oral vs PEG/RBV
Maria Buti-Ferret, MD
4:35 pm - 4:55 pm
Therapeutic Challenges: HIV
Kenneth E. Sherman, MD, PhD
4:55 pm - 5:15 pm
Genotypes 4,5,6: The Forgotten
Patrick Marcellin, MD, PhD
5:15 pm - 5:30 pm
Panel Discussion

 Saturday, September 13

Talk TitleFilter
 
Session 5: Refining the Regimens
8:00 am - 8:20 am
The HCV All-Oral Cocktail: Mixology
Mark S. Sulkowski, MD
8:20 am - 8:40 am
Therapeutic Challenges: Decompensated Cirrhosis, Liver Transplantation
Norah Terrault, MD, MPH
8:40 am - 9:00 am
Real World Experience with DAA regimens
David R. Nelson, MD
9:00 am - 9:20 am
What's Important to the Patient?
Donna M. Evon, PhD
9:20 am - 9:40 am
Panel Discussion
 
Session 6: Global Access to Care
10:00 am - 10:20 am
Global Barriers to HCV Care: Ex-US
Stefan Wiktor, MD
10:20 am - 10:40 am
Delivering HCV Care Beyond the Subspecialist
Guadalupe Garcia-Tsao, MD
10:40 am - 11:00 am
Treating HCV in Resource Limited Environments
Mark Richard Thursz, MD
11:00 am - 11:20 am
HCV Treatment Guidance: AASLD/IDSA
David L. Thomas, MD
11:20 am - 11:40 am
HCV Treatment Guidance: EASL
Markus Peck-Radosavljevic, MD
11:40 am - 12:00 pm
Panel Discussion
12:00 pm - 12:15 pm
Wrap Up: Looking to the Future
Adrian M. Di Bisceglie, MD, FACP

 ‭(Hidden)‬ Custom List View Classes

This program is supported by independent medical educational grants from:

AbbVie
Bristol-Myers Squibb
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck

Salix Pharmaceuticals

No commercial entity was involved in decisions regarding the development of the program and selection of the speakers. In addition, there has not been any condition of purchase, use or recommendation of any products or services associated with the support of the AASLD/EASL HCV Special Conference.